Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports

[1]  M. D'Agostino,et al.  Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  Xuebing Cao,et al.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management , 2014, Orphanet Journal of Rare Diseases.

[3]  L. del Vecchio,et al.  The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family , 2014, Clinical chemistry and laboratory medicine.

[4]  F. Blanco-Vaca,et al.  Sitosterolemia: Diagnosis, Investigation, and Management , 2014, Current Atherosclerosis Reports.

[5]  A. Federico,et al.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis , 2014, Journal of Inherited Metabolic Disease.

[6]  G. Corso,et al.  Sterol profiles in plasma and erythrocyte membranes in patients with Smith-Lemli-Opitz syndrome: a six-year experience , 2011, Clinical chemistry and laboratory medicine.

[7]  L. del Vecchio,et al.  An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations[S] , 2011, Journal of Lipid Research.

[8]  S. Rossi,et al.  Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis , 2011, Journal of Neurology.

[9]  G. Corso,et al.  Plasma levels of conjugated bile acids in newborns after a short period of parenteral nutrition. , 2010, JPEN. Journal of parenteral and enteral nutrition.

[10]  M. D. de Barse,et al.  Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX , 2008, Journal of Inherited Metabolic Disease.

[11]  S. Panico,et al.  Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[12]  D. Campion,et al.  Unusual cerebrotendinous xanthomatosis with fronto‐temporal dementia phenotype , 2005, American journal of medical genetics. Part A.

[13]  M. A. Croce,et al.  Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. , 1997, Journal of lipid research.

[14]  U. Francke,et al.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. , 1991, The Journal of biological chemistry.

[15]  G. Tint,et al.  Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. , 1985, The Journal of clinical investigation.

[16]  A. Batta,et al.  Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. , 1985, Journal of lipid research.